Clevidipine

Structural formula
Structural formula without stereochemistry
General
Surname	Clevidipine
other names	( RS ) -5- O - (Butanoyloxymethyl) 3- O -methyl 4- (2,3-dichlorophenyl) -2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate ( IUPAC )
Molecular formula	C 21 H 23 Cl 2 NO 6
External identifiers / databases
CAS number 167221-71-8 (without configuration information) 167356-40-3 [( R ) -form] 167356-39-0 [( S ) -form] EC number 682-702-2 ECHA InfoCard 100.208.117 PubChem 153994 DrugBank DB04920 Wikidata Q5132338
Drug information
ATC code	C08 CA16
Drug class	Calcium antagonist (L-type)
properties
Molar mass	456.32 g · mol -1
safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed GHS hazard labeling no classification available
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Clevidipine is a drug (a dihydropyridine L-type calcium channel blocker) from the group of calcium antagonists for the rapid reduction of high blood pressure in perioperative situations. The substance was approved in the USA in 2008 and in Switzerland in 2010.

Stereochemistry

Clevidipine contains a stereocenter and consists of two enantiomers. This is a racemate , i.e. a 1: 1 mixture of ( R ) - and ( S ) -form:

Enantiomers of clevidipine
CAS number: 167356-40-3	CAS number: 167356-39-0

Clinical information

Application areas (indications)

Clevidipine is an ultra-short-acting and vascular selective calcium channel blocker from the group of dihydropyridines of the 3rd generation. It is vasodilator, hypotensive and is used intravenously for the rapid reduction of blood pressure in perioperative situations.

Adverse effects (side effects)

Possible adverse effects include lowering blood pressure too much, rapid heartbeat, headache, nausea, and vomiting.

Trade names

• Cleviprex

literature

• Emma D. Deeks, Gillian M. Keating, Susan J. Keam: Clevidipine - A Review of its Use in the Management of Acute Hypertension . In: American Journal of Cardiovascular Drugs . tape 9 , no. 2 , March 1, 2009, p. 117-134 , doi : 10.1007 / BF03256583 .
• Ahmed S. Awad, Michael E. Goldberg: Role of clevidipine butyrate in the treatment of acute hypertension in the critical care setting: a review . In: Vascular Health and Risk Management . tape 6 , 2010, p. 457-464 , PMID 20730061 .
• Abbie L. Erickson, Jeremy R. DeGrado, John R. Fanikos: Clevidipine: a short-acting intravenous dihydropyridine calcium channel blocker for the management of hypertension . In: Pharmacotherapy . tape 30 , no. 5 , May 2010, p. 515-528 , doi : 10.1592 / phco.30.5.515 , PMID 20412001 .
• Ilse M. Espina, Joseph Varon: Clevidipine: a state-of-the-art antihypertensive drug under the scope . In: Expert Opinion on Pharmacotherapy . tape 13 , no. 3 , February 2012, p. 387-393 , doi : 10.1517 / 14656566.2012.651126 .

Studies

• ESCAPE-I: Jerrold H. Levy et al .: Clevidipine Effectively and Rapidly Controls Blood Pressure Preoperatively in Cardiac Surgery Patients: The Results of the Randomized, Placebo-Controlled Efficacy Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery-1 . In: Anesthesia & Analgesia . tape 105 , no. 4 , October 2007, p. 918-925 , doi : 10.1213 / 01.ane.0000281443.13712.b9 , PMID 17898366 .
• ESCAPE-II: Neil Singla et al: Treatment of Acute Postoperative Hypertension in Cardiac Surgery Patients: An Efficacy Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery-2 (ESCAPE-2), a Randomized, Double-Blind, Placebo-Controlled Trial . In: Anesthesia & Analgesia . tape 107 , no. 1 , July 2008, p. 59-67 , doi : 10.1213 / ane.0b013e3181732e53 , PMID 18635468 .
• ECLIPSE: Solomon Aronson et al: The ECLIPSE Trials: Comparative Studies of Clevidipine to Nitroglycerin, Sodium Nitroprusside, and Nicardipine for Acute Hypertension Treatment in Cardiac Surgery Patients . In: Anesthesia & Analgesia . tape 107 , no. 4 , October 2008, p. 1110-1121 , doi : 10.1213 / ane.0b013e31818240db , PMID 18806012 .
• VELOCITY: Charles V. Pollack, Joseph Varon, Norman A. Garrison, Ramin Ebrahimi, Lala Dunbar, W. Frank Peacock IV: Clevidipine, an Intravenous Dihydropyridine Calcium Channel Blocker, Is Safe and Effective for the Treatment of Patients With Acute Severe Hypertension . In: Annals of Emergency Medicine . tape 53 , no. 3 , March 2009, p. 329-338 , doi : 10.1016 / j.annemergmed.2008.04.025 , PMID 18534716 .

Individual evidence

1. ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
2. ↑ The Medicines Company's Cleviprex (TM) Receives FDA Approval , PM of the manufacturer August 4, 2008, accessed on March 24, 2014.
3. ↑ FDA Approved Cardiovascular Medicines (2002 - present) (Engl.) ( Memento of 24 March 2014 Internet Archive ), site of the US Food and Drug Administration (FDA), accessed March 24, 2014.
4. ↑ Approved preparations by preparation name (January 2014) ( Memento of the original from March 24, 2014 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. , Swissmedic website, accessed on March 24, 2014 
5. ↑ Cleviprex - Swissmedic-Registration , website of ODDB.org, accessed on March 24, 2014.
6. ↑ Rote Liste Service GmbH (Ed.): Rote Liste 2017 - drug directory for Germany (including EU approvals and certain medical devices) . Rote Liste Service GmbH, Frankfurt / Main, 2017, edition 57, ISBN 978-3-946057-10-9 , p. 171.
7. ^ ^{A b} Clevidipine Prescribing Information. (English) ( Memento from September 2, 2013 in the Internet Archive ), website of the manufacturer, accessed on March 24, 2014.

This article is about a health issue. It is not used for self-diagnosis and does not replace a diagnosis by a doctor. Please note the information on health issues !